ClinicalTrials.gg
Sign In
RecruitingNCT07223086Updated Jun 11, 2026

Use of Tinted Contact Lenses for Concussion-Related Light Sensitivity

An interventional study of Narrow band (tinted) contact lenses and broad band (clear) contact lenses in Concussion, Mild, Photophobia and Contact Lens, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to gather pilot data on the effectiveness of daily disposable tinted contact lenses in reducing photophobia (light sensitivity) following a concussion, with the goal of facilitating the return to work or school.

02

Conditions studied

  • Concussion, Mild
  • Photophobia
  • Contact Lens

Keywords

  • Mild concussion
  • tinted contact lenses
  • light sensitivity
03

In context

Brain Concussion

637 studies on the registry are indexed under Brain Concussion; 163 are open to participants now.

This study's planned enrollment of 60 is close to the median of 63 across 446 interventional studies indexed under Brain Concussion.

Browse Brain Concussion studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,421 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Browse University of Alabama at Birmingham studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed mild traumatic brain injury (concussion)
  • age 18 or older
  • Within 24 months of initial injury
  • experiencing symptoms of photophobia (light sensitivity), increased photophobia since the injury, or no symptoms of photophobia

Exclusion criteria

Exclusion Criteria:

  • moderate or severe concussion
  • active infection or inflammation that contradicts the use of soft contact lenses
  • subjects unable to safely perform insertion and removal of the contact lenses
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Participants with concussion and light sensitivity fit with broad band (clear) contact lens

    UPSIS-2 scale 15-60, eligible participants score greater than or equal to 26 are fit in broad band (clear) contact lenses.

    Device: broad band (clear) contact lenses

  • Active comparator
    Participants with concussion and light sensitivity fit with narrow band (tinted) contact lens

    UPSIS-2 scale 15-60, eligible participants score greater than or equal to 26 are fit in narrow wavelength (tinted) contact lenses.

    Device: Narrow band (tinted) contact lenses

Interventions

  • DeviceNarrow band (tinted) contact lenses

    Participants will receive these contacts based on the results of the Utah Photophobia Symptom Impact Scale (survey).

    Also known as: Altius contact lenses

  • Devicebroad band (clear) contact lenses

    Participants will receive these contacts based on the results of the Utah Photophobia Symptom Impact Scale (survey).

    Also known as: BioTrue One Day, Infuse daily disposable contact lenses, Clariti 1 Day clear contact lenses

06

What researchers measure

Primary outcomes

  1. Number of participants that improved symptoms of light sensitivity with narrow band (tinted) contact lenses

    Improvement in the Utah Photophobia Symptom Impact Scale version 2 (UPSIS-2) on a scale of 15-60. Anything over 26 is considered significant.

    Time frame: Baseline, 1 week

07

Study locations

1 of 1 sites recruiting
  • UAB Eye Care
    Birmingham, Alabama 35294, United States
    Recruiting
    • Candice I Turner, OD · Contactciturner@uab.edu · (205)934-0997
    • Katherine K Weise, OD · Contactkweise@uab.edu · (205) 934-6758
    • Candice I Turner, OD · Principal investigator
    • Katherine K Weise, OD · Sub investigator
    • Heidi Hernandez, OD · Sub investigator
    • Mallory Wright, OD · Sub investigator
    • Thom Houston, MD · Sub investigator
    • Mark Swanson, OD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 248 non-industry interventional studies with no phase under Brain Concussion, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 7 months is below that.

Counting every sponsor, half of 264 studies reached it within 28 months; a quarter within 19 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 31, 2025
StartActual
May 8, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 1, 2027
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07223086
Lead sponsor
University of Alabama at Birmingham
Responsible party
Candice Turner (Associate Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Oct 31, 2025
Start date
May 8, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jun 11, 2026

Study contacts

Candice I Turner, OD
Contact
citurner@uab.edu
(205)934-0997
Katherine K Weise, OD
Contact
kweise@uab.edu
(205) 934-6758
Candice I Turner, OD
principal investigator · University of Alabama at Birmingham School of Optometry

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Brain Concussion →

Other studies from this sponsor

University of Alabama at Birmingham →

Start the discussion